基于昆素的UCHL5抑制剂作为20S抑制之外的下一代蛋白质酶向抗癌剂
Tae-Hee Han1, Joohan Lee2, Joo-Young Im3
1Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, South Korea; Department of Biomolecular Science, KRIBB School of Bioscience, Korea National University of Science and Technology (UST), Daejeon 34113, South Korea.
Journal of advanced research
|February 12, 2026
概括
一种新型的昆素衍生物DK-7可以选择性地抑制UCHL5,一种蛋白酶组分. 这种化合物有效触发癌细胞亡并克服博特佐米布耐药性,显示出固体瘤治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 癌细胞利用细胞内网膜 (ER) 应激和展开的蛋白质反应 (UPR) 进行生存.
- 无素-蛋白酶体系统 (UPS) 对于蛋白质平衡至关重要,并且在瘤中经常受到失调.
- 现有的蛋白酶体抑制剂在固体瘤和获得的耐药性方面面临有效性限制.
研究的目的:
- 为了发现诺素基分子准UCHL5,一个蛋白质酶调节粒子组成部分.
- 评估这些分子在癌症中克服博特佐米布耐药性的潜力.
- 描述化合物的作用机制和抗癌功效.
主要方法:
- 选用于ER应激诱导的昆素衍生物库.
- 酶测定,生物物理结合,分子对接和质谱测试以识别和验证UCHL5标.
- 在体外评估各种癌症细胞系的抗癌活性,包括对博雷佐米布耐药的模型.
- 使用异种移植小鼠模型进行体内评估.
主要成果:
- 昆素衍生物DK-7被确定为一种强效和选择性的UCHL5抑制剂.
- 在没有抑制20S蛋白酶体活性的情况下,DK-7诱导了无处不在的蛋白质积累,ER压力和亡.
- DK-7在固体瘤和抗博特佐米布多发性髓瘤细胞中显著降低了细胞活力.
- 在异种移植模型中,口服DK-7抑制了瘤生长.
结论:
- DK-7选择性地准UCHL5,诱导ER压力和亡,并克服博特佐米布耐药性.
- 抑制UCHL5代表了对固体瘤的有前途的治疗策略.
- 基于诺素的二维基因酶抑制剂提供了潜在的下一代蛋白质酶向治疗,具有广泛的临床适用性.
更多相关视频
相关概念视频
The Proteasome
10.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.3K
The Proteasome
1.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
The Proteasome
4.6K
4.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
597
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
597
Eukaryotic Transcription Inhibitors
11.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
The Proteasome Structure
1.8K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.8K


